Value Line - The Most Trusted Name in Investment Research - Stock Quotes

Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2014-09-12)Premium Content

Exelixis Inc (EXEL)

2014-11-25@16:05:10 ET
Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2 (BIZ)

2014-11-24@04:23:11 ET
Exelixis announces positive preliminary results from Phase I melanoma trial (DTM)

2014-11-19@08:37:16 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@08:37:06 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@08:36:55 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@08:36:45 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@08:36:34 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@08:36:23 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:54 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:43 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:33 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:23 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:11 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-19@07:13:00 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2014-11-18@09:00:00 ET
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA (PRN)

2014-11-18@03:51:27 ET
Exelixis Q3 net loss down (DTM)

2014-11-18@03:49:39 ET
Exelixis announces positive results from Phase II NSCLC trial (DTM)

2014-11-16@04:20:03 ET
Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib (BIZ)

2014-11-11@04:34:02 ET
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles (MTO)

2014-11-10@11:48:41 ET
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles (MTO)